Shots:

• The first patient has been dosed in the P-III SWIFT-2 trial assessing the safety and efficacy of GSK3511294 (GSK’294) in SEA
• The planned P-III program involves three studies- SWIFT 1- SWIFT 2 and the NIMBLE study that will assess the efficacy and safety of GSK’294 in ~2-450 patients with severe eosinophilic asthma
• GSK’294 (SC- every 6mos.) is an anti-IL-5 mAb- currently in development for the treatment of SEA and has progressed from P-I to P-III studies in three and a half years

 ­ Ref: GSK | Image: News Medical